Novartis AG (NVSN)
Bolsa Mexicana de Valores · Mexico · prices in MXN · close of 27 Oct 2026
Key indicators
| Last close | MXN 2,911.00 |
|---|---|
| 52-week range | 2,298.00 – 2,922.00 |
| Return, 1 month / 3 months | +13.2% / +6.6% |
| Return, 1 year / 3 years | +23.9% / +79.3% |
| Trend | Uptrend |
| RSI (14) | 70 |
| Volatility (1 year) | 27.4% |
| Worst drawdown (1 year) | -18.9% |
| Average daily value traded | 0.10M MXN |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Novartis is a pharmaceutical company based in Switzerland that discovers, develops and makes prescription medicines. Its products treat conditions such as cancer, heart disease, immune disorders and eye disease, and it also supplies generic drugs through its Sandoz business. Customers are mainly hospitals, doctors, pharmacies and health systems around the world, along with patients who use its treatments. The company also makes contact lenses and eye-care products through its Alcon division.
The shares are listed on the Bolsa Mexicana de Valores in Mexico under the code NVSN, and the price on this page is in Mexican pesos (MXN). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Novartis AG (NVSN) trades on the Bolsa Mexicana de Valores in Mexico. It last closed at MXN 2,911.00 on 27 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 158 of 361 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 23.9% and over the last three months it rose 6.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Bolsa Mexicana de Valores
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 61 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 9.6% | ||
| From 52-week high | -0.4% | ||
| Momentum | 60 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 6.6% | ||
| 6-month return | 10.9% | ||
| 12-month return, skipping the last month | 9.4% | ||
| Stability (higher is calmer) | 61 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 27.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -18.9% | ||
| Liquidity | 22 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.10M MXN | ||
| Zero-volume days | 48.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +3.2% |
|---|---|
| 1 month | +13.2% |
| 3 months | +6.6% |
| 6 months | +10.9% |
| 1 year | +23.9% |
| 3 years | +79.3% |
| 5 years | +114.6% |
Signals
| 50-day / 200-day average | 2,612.34 / 2,656.46 |
|---|---|
| Golden / death cross (60 days) | Death, 19 days ago |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 48.14 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 12 Mar 2025 | MXN 80.5668 |
| 7 Mar 2024 | MXN 63.1273 |
| 9 Mar 2023 | MXN 59.7559 |
| 8 Mar 2022 | MXN 43.8631 |
| 4 Mar 2021 | MXN 62.9980 |
| 3 Mar 2020 | MXN 56.1713 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Bolsa Mexicana de Valores; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.